Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil?

Twelves, Chris and Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496 2001. Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? Expert Opinion on Pharmacotherapy 2 (9) , pp. 1495-1505. 10.1517/14656566.2.9.1495

Full text not available from this repository.

Abstract

The fluoropyrimidines have been used in the treatment of a number of tumour types over the past 40 years. Particular attention has focused on the use of 5-fluorouracil (5-FU) in colorectal cancer for which, until recently, there has been a lack of other effective chemotherapy. In an attempt to optimise the efficacy of fluoropyrimidines, a number of approaches have been used. These include alternative methods of iv. scheduling, the use of co-factors and the development of oral compounds. The aim of oral agents is to satisfy patient preference while maintaining the efficacy of sustained drug exposure seen with prolonged or continuous infusions of iv. 5-FU. One such oral compound is uracil-tegafur (UFT), which combines tegafur (ftorafur, a 5-FU prodrug) and uracil in a 1:4 molar ratio. UFT first entered Phase I trials in Japan over 20 years ago but has only recently received significant exposure in Phase II and III trials. Results from a number of Phase III studies in Europe and in the US are now becoming available. With UFT recently approved for colorectal cancer in many European countries, although not in the US, it is timely to review the current situation and future prospects for this agent.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences Medicine European Cancer Stem Cell Research Institute (ECSCRI)
Subjects:	Q Science > Q Science (General) R Medicine > R Medicine (General)
Uncontrolled Keywords:	cancer, cytotoxic, oral fluoropyrimidines, UFT, uracil-tegafur.
Publisher:	Informa Healthcare
ISSN:	1465-6566
Last Modified:	22 Jun 2023 10:01
URI:	https://orca.cardiff.ac.uk/id/eprint/69205

Citation Data

Cited 6 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item